ImmunityBio
Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune SystemCareers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Recent News
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both
T Cell and Antibody Immunity
Learn more about the science behind COVID-19
Recent News
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both
T Cell and Antibody Immunity
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Careers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
Learn more about the science behind COVID-19
Contact Us
© 2020 ImmunityBio, Inc. All rights reserved.